Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as [14C] Antaitavir Hasophate
Antaitavir Hasophate · 1 trial · 1 indication
To investigate the pharmacokinetics of total radioactivity in plasma after oral \[14C\] Antaitavir Hasophate in healthy subjects, and the distribution ratio of total radioactivity in whole blood and plasma
Percent (%) of each radiolabeled drug-related material (parent and each metabolite) will be determined in plasma, urine and feces.
| Arm | Type | Description |
|---|---|---|
| [14C] Antaitavir Hasophate | EXPERIMENTAL | Eligible healthy male subjects received a single oral 100 mg (radioactivity of 200µCi) dose of \[14C\] Antaitavir Hasophate |
| Name | Type | Description |
|---|---|---|
| [14C] Antaitavir Hasophate | DRUG | 100 mg suspension containing 200µCi of \[14C\] Antaitavir Hasophate |
Inclusion Criteria: * signing of informed consent * Weight: Body mass index (BMI) is 19.0\~28.0 kg/m2 * Subjects are able to communicate well with the investigators and be able to complete the trial according to the process Exclusion Criteria: * Those who are known to have allergy history or alle...
Antaitavir Hasophate is an investigational small molecule developed by Sunshine Biopharma Inc. (ticker SBFM). It has been studied in a Phase 1 clinical trial, and its specific therapeutic indications have not been disclosed. It is not approved for any use.
Antaitavir Hasophate is being developed by Sunshine Biopharma Inc., which trades under the ticker SBFM. The company sponsored the Phase 1 trial of the drug.
Antaitavir Hasophate is in Phase 1 development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug remains investigational and has not been approved by the FDA or any other regulatory agency.
Antaitavir Hasophate has been evaluated in one completed Phase 1 trial, NCT05446233, titled ADME Study of [14C] Antaitavir Hasophate in Healthy Male Subjects. The trial enrolled 6 healthy male participants in China and was an uncontrolled, non-randomized study.
Yes, [14C] Antaitavir Hasophate is an alternative name for Antaitavir Hasophate. The bracketed label indicates a carbon-14 radiolabeled version used in the ADME study, NCT05446233, to track the drug's absorption, distribution, metabolism, and excretion.